LS CancerDiag
Founded: 2013 Category: Health & Medical Technology City: Helsinki
This company is older than 10 years and is no longer applicable to the trending list
LS CancerDiag Ltd is committed to reducing cancer mortality rates with a simple diagnostic method that reliably detects an inherited cancer-causing condition prior to cancer. Our vision is to see DiagMMR® as the new Gold Standard for Lynch syndrome detection.
Lynch syndrome is the main cause of hereditary colorectal cancers and it also causes a broad spectrum of other tumors. With a significant proportion of the world’s population carrying the Lynch syndrome mutation, there are potentially tens of millions under a severe risk for being affected by LS.
Our groundbreaking DiagMMR™ assay is an easy functional test that can be used for diagnosis of MMR deficiency i.e. Lynch syndrome (previously known as Hereditary NonPolyposis Colorectal Cancer; HNPCC).
Our mission is to save lives through an innovation that dramatically simplifies diagnostics of Lynch syndrome globally by delivering predictive and accurate results with a fast, unique and cost-efficient method.